ストックスクリーナーアプリを入手
1.0179
0.78%
0.0079
An 2 Therapeutics Inc (ANTX) 最新ニュース
22q11.2 Deletion Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Nobias Therapeutics, Zynerba Pharma, Bausch Health Americas - The Globe and Mail
Cognition Therapeutics Presents Poster of Participant - GlobeNewswire
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - BioSpace
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Yahoo Finance
Intellia Presents Positive Results from the Phase 2 Study - GlobeNewswire
Viking Therapeutics Inc (VKTX) Q3 2024 Earnings Call Highlights: Strong Financial Position Amid ... - Yahoo Finance
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM - GlobeNewswire
Neumora Therapeutics: A Story Of A Class II Biotech (NASDAQ:NMRA) - Seeking Alpha
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress - StockTitan
Summit Therapeutics Inc (SMMT) Q2 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease - Business Wire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. - GlobeNewswire
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress - StockTitan
Tvardi Therapeutics Announces Presentation of TTI-101 Preclinical Data Providing Mechanistic Rationale for Phase 2 REVERT IPF Clinical Trial at CHEST 2024 - Business Wire
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update - GlobeNewswire
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 - StockTitan
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 - Yahoo Finance
Araris Doubles Down With Dual-payload ADC - BioProcess Online
Black Diamond Therapeutics Announces Initial Phase 2 Data - GlobeNewswire
Ildikó Enyedi working on her new feature, Silent Friend - Cineuropa
Boss Brown calls on Ayr players to step up after losing top scorer for season - Ayr Advertiser
Black Diamond Therapeutics to Host Webcast Presentation of - GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - Yahoo Finance
Scott Brown admits Anton Dowds injury is huge blow for Ayr United as he challenges others to step up - Daily Record
Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa
Adicet Bio reports promising ADI-001 therapy data - Investing.com
Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM
Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting - BioSpace
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire
Agatha All Along Episode 2 Cast & Characters Guide (Photos) - The Direct
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire
iView Therapeutics completes enrollment in phase 1/2 trial for ophthalmic eyelid wipe for the treatment of dry eye disease - Ophthalmology Times
VERV CLASS ACTION: Verve Therapeutics, Inc. Stockholders - GlobeNewswire
IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients - PR Newswire
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern - Yahoo Finance
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 - Yahoo Finance
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysi - Yahoo Finance
Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration - PR Newswire
Intellia Therapeutics to Present Data from the Phase 2 - GlobeNewswire
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting - Yahoo Finance
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) - GlobeNewswire
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 - Newsfile
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations - GlobeNewswire
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial - GlobeNewswire
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts - Yahoo Finance
Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients (SLNO) - Seeking Alpha
Innovo Therapeutics Inc. Announces Phase 2 Clinical Results Demonstrating the Innovative Efficacy of INV-001 for the Treatment of Post-thyroidectomy Scars - Winchester Herald Chronicle
Director J Singleton Sells 5,700 Shares of Viking Therapeutics Inc (VKTX) - Yahoo Finance
Cognition Therapeutics Publishes EEG Findings from Phase 2 - GlobeNewswire
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - Yahoo Finance
iTeos Therapeutics Announces Late-Breaking Oral - GlobeNewswire
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 - Yahoo Finance
Scorpion Therapeutics to Present STX-478 Initial Phase 1/2 Data at ESMO Congress 2024 - Business Wire
Why Is Viking Therapeutics, Inc. (VKTX) the Best Diabetes Stock to Buy Now? - Yahoo Finance
Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year? - Yahoo Finance
Tempest Announces Successful End-of-Phase 2 Meeting with - GlobeNewswire
2.66%
0.55%
大文字化:
|
ボリューム (24 時間):